Coexistence of homozygous factor V Leiden mutation and antiphospholipid antibodies in two patients presented with Budd-Chiari syndrome

Haematologia

Volumn 32, Issue 1, 2002, Pages 73-77

  Diz Kucukkaya, Reyhan ^a   Demir, Kadir ^a   Yenerel, Mustafa N ^a   Nalcaci, Meliha ^a   Kaymakoglu, Sabahattin ^a   Inanc, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antiphospholipid antibodies; Budd Chiari syndrome; Homozygous factor V Leiden mutation; Portal vein thrombosis; Recurrent fetal loss; Splenic vein thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DIURETIC AGENT; HEPARIN; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; ASCITES; BUDD CHIARI SYNDROME; CASE REPORT; COMORBIDITY; DEEP VEIN THROMBOSIS; FEMALE; FETUS WASTAGE; GENE MUTATION; HOMOZYGOSITY; HUMAN; PATHOGENESIS; PORTAL VEIN THROMBOSIS; RECURRENT DISEASE; SPLENIC VEIN; VEIN THROMBOSIS;

ABORTION, HABITUAL; ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FACTOR V; FAMILY HEALTH; FEMALE; HEPATIC VEIN THROMBOSIS; HOMOZYGOTE; HUMANS; MIDDLE AGED; PORTAL VEIN; PREGNANCY; SPLENIC VEIN; THROMBOSIS;

EID: 0036901772     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: 10.1163/156855902760262790     Document Type: Article

References (20)

1. Janssen, H. Y. L. A., Meinardi, J. R., Vleggaar, F. P., van Uum, S. H. M., Haagsma, E. B., van der Meer, F. J. M., van Hattum, J., Chamuleau, R. A. F. M., Adang, R. P., Vandenbroucke, J. P, van Hoek, B., Rosendaal, F. R., Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study, Blood 96, 2364 (2000).
2. Denninger, M. H., Chait, Y., Casavedall, N., Hillaire, S., Guillin, M. C., Bezeaud, A., Erlinger, S., Briere, J., Valla, D., Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors, Hepatology 31, 587 (2000).
3. Harris, E. N., Annotation: Antiphospholipid antibodies, Br. J. Haematol. 74, 1 (1990).
4. Oosting, J. D., Derksen, R. H. W. M., Robbink, I. W. G., Hackeng, T. M., Bouma, B. N., de Groot, P. G., Antiphospholipid antibodies directed against a combination of phospholipids with thrombin, protein C or protein S, Blood 81, 2618 (1993).
5. D'Cruz, D., Hughes, G., Antibodies, thrombosis and the endothelium, Br. J. Rheumatol. 33, 2 (1994).
6. Santoro, S. S., Antiphospholipid antibodies and thrombotic predisposition: Underlying pathogenetic mechanisms, Blood 83, 2389 (1994).
7. Asherson, R. A., Khamashta, M. A., Hughes, G. R. V., The hepatic complications of the antiphospholipid antibodies, Clin. Exp. Rheumatol. 9, 341 (1991).
8. Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., Reitsma, P. H., Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature 369, 64 (1994).
9. Dahlbäck, B., Inherited thrombophilia: Resistance to activated protein C as a pathogenetic factor of venous thromboembolism, Blood 85, 607 (1995).
10. Alarcon-Segovia, D., Ruiz-Argüelles, G. J., Garces-Eisele, J., Ruiz-Argüelles, A., Inherited activated protein C resistance in a patient with familial primary antiphospholipid syndrome, J. Rheumatol. 23, 2162 (1996).
11. Aznar, J., Villa, P., Espaňa, F., Estelles, A., Grancha, S., Falco, C., Activated protein C resistance phenotype in patients with antiphospholipid antibodies, J. Lab. Clin. Med. 130, 202 (1997).
12. Matsuda, J., Gotoh, M., Gohcki, K., Kawasugi, K., Tsukamoto, M., Saitoh, N., Resistance to activated protein C activity of an anti-β2-glycoprotein I antibody in the presence of β-2-glycoprotein I, Br. J. Haematol. 90, 204 (1995).
13. Denninger, M. H., Helley, D., Valla, D., Guillin, M. C., Prospective evaluation of the prevalence of factor V Leiden mutation in portal or hepatic vein thrombosis, Thromb. Haemost. 78, 1297 (1997).
14. Rosendaal, F. R., Koster, T., Vandenbroucke, J. P., Reitsma, P. H., High risk of thrombosis in patients homozygous for factor V Leiden (Activated protein C resistance), Blood 85, 1504 (1995).
15. Rees, D. C., The population genetics of Factor V Leiden (Arg506Gln), Br. J. Haematol. 95, 579 (1996).
16. Malia, R. G., Kitchen, S., Greaves, M., Preston, F. E., Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies, Br. J. Haematol. 76, 101 (1990).
17. Ames, P. R. J., Tommasino, C., Iannaccone, L., Brillante, M., Cimino, R., Brancaccio, V., Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies. A crucial role for acquired free protein S deficiency, Thromb. Haemost. 76, 190 (1996).
18. 506 → Gln mutation in patients with antiphospholipid antibodies, Lupus 5, 303 (1996).
19. Ames, P. R. J., Tommasino, C., D'Andrea, G., Iannaccone, L., Brancaccio, V., Margaglione, M., Thrombophilic genotypes in subjects with idiophatic antiphospholipid antibodies. Prevalance and significance, Thromb. Haemost. 79, 46 (1998).
20. Grandone, E., Margaglione, M., Colaizzo, D., d'Addeda, M., Cappucci, G., Vecchione, G., Scianname, N., Pavone, G., Di Minno, G., Factor V Leiden is associated with repeated and recurrent unexplained fetal losses, Thromb. Haemost. 77, 822 (1997).